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5-hydroxytryptamine (5-HT) is a key regulator of muscle contraction in parasitic ﬂatworms. In Schisto-
soma mansoni, the myoexcitatory action of 5-HT is effected through activation of a serotonergic GPCR
(Sm.5HTRL), prioritizing pharmacological characterization of this target for anthelmintic drug discovery.
Here, we have examined the effects of several aporphine alkaloids on the signaling activity of a heter-
ologously expressed Sm.5HTRL construct using a cAMP biosensor assay. Four structurally related natural
products e nuciferine, D-glaucine, boldine and bulbocapnine e were demonstrated to block Sm.5HTRL
evoked cAMP generation with the potency of GPCR blockade correlating well with the ability of each
drug to inhibit contractility of schistosomule larvae. Nuciferine was also effective at inhibiting both basal
and 5-HT evoked motility of adult schistosomes. These data advance our understanding of structure-
afﬁnity relationships at Sm.5HTRL, and demonstrate the effectiveness of Sm.5HTRL antagonists as
hypomotility-evoking drugs across different parasite life cycle stages.
© 2016 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Over 200 million people worldwide are infected with parasitic
schistosome ﬂatworms, which cause the disease schistosomiasis.
The drug praziquantel (PZQ) has served as the stalwart of anti-
schistosomal therapy since the 1980s. However several features of
PZQ are less than ideal, and the lack of research into next genera-
tion antischistosomal therapies makes the specter of emergence of
PZQ-resistant strains potentially devastating.
Screening for antischistosomal drugs that impair parasite
mobility is a logical approach toward anthelmintic drug discovery
(Pax et al., 1996; Ribeiro et al., 2005): indeed, neuromuscular
impairment is considered a key component of the clinical efﬁcacy
of PZQ. Defects and shape malformations therefore form the basis
of many antischistosomal phenotypic screens (Abdulla et al., 2009;
Paveley et al., 2012; Mansour et al., 2016; Singh et al., 2016). From a
target-based screening approach there is also considerable interest
in dissecting the neuromuscular physiology of schistosomes tourch St SE, Minneapolis, MN,
t).
Ltd on behalf of Australian Society fidentify key signaling nodes that coordinate excitable cell activity.
Resolution of the contribution from G protein coupled receptors
(GPCRs) to parasite neuromuscular signaling is especially alluring,
given the preponderance of GPCR ligands among existing
therapeutics.
In this context, several recent studies have begun to establish
the role(s) of individual GPCRs within the excitable cell niche (El-
Shehabi et al., 2012; Patocka et al., 2014; Chan et al., 2015;
MacDonald et al., 2015). Of relevance to this study, is the identiﬁ-
cation of a serotonergic GPCR (Sm.5HTRL) that has been shown by
RNAi approaches to control larval and adult wormmotility (Patocka
et al., 2014). Knockdown of this receptor, expressed across the
parasite life cycle (Protasio et al., 2012), caused hypoactive motor
phenotypes in schistosomules and adult worms consistent with the
myoexcitatory role of 5-HT (Patocka et al., 2014). Knockdown of the
Sm.5HTRL homologue in free living planarians (Dj-S7.1R, see com-
panion paper, Chan et al., 2016a) also causes hypomobility (Chan
et al., 2015).
We recently applied a cAMP biosensor technology to proﬁle
the ligand binding speciﬁcities of this GPCR. This approach revealed
properties and a pharmacological divergence of Sm.5HTRL
from the closest human GPCR homolog (Hs.5HTR7) that furtheror Parasitology. This is an open access article under the CC BY-NC-ND license (http://
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vulnerable node for anthelmintic development (Chan et al., 2016b).
The chemical screening data demonstrated a potent, and long
lasting inhibition evoked by the ergot alkaloid bromocriptine at
Sm.5HTRL (evidenced also for the planarian S7.1R in the companion
paper (Chan et al., 2016a)), and highlighted several Sm.5HTRL an-
tagonists with dimethoxyisoquinoline substructures. Here, we
apply the cAMP biosensor to expand upon this growing under-
standing of structure-activity relationships at Sm.5HTRL by exam-
ining the effects of several aporphine alkaloids containing
methoxyisoquinoline moieties.
Aporphines are tetracyclic alkaloids that display a broad range
of pharmacological activities encompassing afﬁnity for bio-
aminergic receptors. A clinically well-known example is apomor-
phine, a synthetic morphine derivative used clinically as an anti-
Parkinsonian agent due to efﬁcacy at dopaminergic GPCRs.
Several aporphine compounds have previously been demon-
strated to impair neuromuscular function in a variety of helminth
parasites (Ayers et al., 2007; Chan et al., 2014; Lin et al., 2014),
although the molecular target of these drugs in parasites is
uncharacterized. The afﬁnity of aporphinoids for mammalian 5-HT
GPCRs (Munusamy et al., 2013; Ponnala et al., 2014, 2015; Farrell
et al., 2016) was especially intriguing to us in this context. Here,
we examine the action of four aporphinoid natural products
at Sm.5HTRL and demonstrate a close correlation between recep-
tor blockade and a hypomotive action on schistosome larvae and
adults.2. Materials and methods
2.1. Chemicals
Aporphine derivatives were obtained from the vendors indi-
cated: R-()-apomorphine (Sigma Aldrich, A4393), ()nuciferine
(Cerilliant, PHY83282), D-Glaucine (Santa Cruz Biotechnology, sc-
490895), (þ)boldine (Sigma Aldrich, 67592), (þ)-Bulbocapnine
(Santa Cruz Biotechnology, sc-257199). Other chemicals sourced for
assays were 3-Isobutyl-1-methylxanthine (Sigma Aldrich, I5879),
serotonin (Sigma Aldrich, H9523) and forskolin (Cell Signaling
Technology, 3828).2.2. Cell culture and cAMP assays
HEK293 cells (ATCC CRL-1573.3) were cultured in growth me-
dia (DMEM, 10% heat inactivated fetal bovine serum, penicillin
(100units/mL), streptomycin (100 mg/mL) and L-glutamine
(290 mg/mL)) and used between passages 5e25. For GPCR heter-
ologous expression and functional assays, cells were transfected
(Lipofectamine, 2000) at 80% conﬂuency approximately 16 h after
seeding on T-25 culture ﬂasks with a 1:1 ratio of Sm.5HTRL and the
pGloSensor 22-F plasmid (Promega). Sm.5HTRL was codon opti-
mized for human expression and subcloned into the pcDNA3.1()
mammalian expression vector. Sm.5HTRL (GenBank accession,
KX150867) is a longer form of the Sm.5HTR originally reported by
Patocka et al. (Patocka et al., 2014). The following day, cells were
trypsinized, centrifuged (300 g/5 min), resuspended in DMEM
supplemented with 1% dialyzed FBS (Gibco) and plated in 96 well,
solid white plates (Corning, cat # 3917). After overnight culture to
allow adherence, media was exchanged for assay buffer (HBSS
supplemented with 0.1% BSA, 20 mM HEPES (pH 7.4), and Glo-
Sensor reagent (Promega)). cAMP-luminescence assays were per-
formed in the presence of phosphodiesterase inhibitor (IBMX,
200 mM) using a GloMax®-Multi Detection System plate reader
(Promega).2.3. Schistosomule mobility assays
Biomphalaria glabrata snails exposed to Schistosoma mansoni
miracidia (Strain PR-1) were provided by BEI Resources (NR-
21961). Schistosomules were obtained by mechanical trans-
formation from shed cercariae as described in (Chan et al., 2016b).
Brieﬂy, cercariae were shed by exposure to light (1.5 h), vortexed
in 50 mL conical tubes (3  45secs, each separated by 3 min on
ice), and tails were removed by gradient centrifugation (24 ml
Percoll, 4 ml 10X EMEM,1.5 ml penicillin-streptomycin, 1 ml of 1M
HEPES in 0.85% NaCl, 9.5 ml distilled water) at 500 g/15 min at
4 C. Tails were discarded (supernatant fraction) and pelleted
schistosomules were resuspended in modiﬁed Basch media
(lacking serotonin) and incubated (37 C, 5% CO2) before con-
ducting mobility assays. Drugs were added to schistosomules in
24 well plates (~200 schistosomules/0.5 mL media per well) at a
20x concentration (i.e. 25 mL stock/500 mL schistosomules),
mixed, and schistosomules were incubated for 30 min (37 C/5%
CO2) prior to acquiring videos of schistosome movement (1 min
video recording per well) using a Nikon Coolpix 5700 camera
afﬁxed to a Nikon Eclipse TS100microscope (10x objective). Worm
mobility was quantiﬁed by processing videos through ImageJ us-
ing the WrmTrck plugin to obtain a measurement for the body
length of each schistosomule over the duration of the recording.
Mobility was deﬁned by quantifying the number of times per
minute that the worm body length deviated from the average by
over 20%. S. mansoni protocols were approved by the Iowa State
University Institutional Biosafety Committee.
2.4. Adult schistosome mobility assays
Female Swiss Webster mice infected with Schistosoma mansoni
cerceria (Strain PR-1) were obtained from BEI Resources (Cat.
number NR-34792) and sacriﬁced 6e8 weeks post-infection. Adult
S. mansoni were recovered from the mesenteric vasculature by
portal perfusion (Chan et al., 2016b). Mice were anesthetized in a
CO2 chamber, sacriﬁced by cervical dislocation, and perfused with
sodium citrate (25 mM). Adult schistosomes harvested from the
mesenteric veins were washed in RPMI media supplemented with
penicillin (100units/mL), streptomycin (100 mg/mL) and 25 mM
HEPES and then transferred to RPMI media supplemented with
2 mM glutamine and 5% heat inactivated FBS. Worms were incu-
bated overnight at 37 C, 5% CO2 before conducting mobility as-
says. Recordings of adult schistosome movement were acquired
using a Zeiss Discovery v20 stereomicroscope and a QiCAM 12-bit
cooled color CCD camera at a rate of four frames per second over
one minute. Videos of female worms were acquired at 7.6x
magniﬁcation, 30mm ﬁeld of view and videos of malewormswere
acquired at a 5.1x magniﬁcation, 45 mm ﬁeld of view. Movement
was quantiﬁed from video recordings according to the protocol
described in Patocka et al. (2014). Image (.tiff) stacks were im-
ported into ImageJ and converting to binary format, representing
the worm body area as a measurement of pixels in each frame. The
difference in pixels resulting from subtracting the value of one
frame (n) from the next in the sequence (nþ1), expressed as a
percentage of the pixels in the initial frame (n), provided a mea-
surement of worm movement over a period of 0.25secs. By per-
forming this measurement for each frame in the video, an average
length was determined for the cohort recorded. Values represent
the mean(±)standard deviation of at least three independent ex-
periments. Signiﬁcance values were obtained by unpaired t-tests
and represented as (*) p < 0.05, (**) p < 0.01. Animal work was
carried out with the oversight and approval of the Laboratory
Animal Resources facility at the Iowa State University College of
Veterinary Medicine.
Fig. 1. Aporphine alkaloid natural products are Sm.5HTRL antagonists. (A) Structures of apomorphine, a semi-synthetic aporphine, and four naturally occurring aporphines
containing methoxyquinoline substructure (nuciferine, D-glaucine, boldine and bulbocapnine). (B) Effects of aporphines on Sm.5HTRL dependent cAMP generation. HEK293 cells
co-transfected with the 22-F cAMP biosensor and Sm.5HTRL were ﬁrst treated with the either DMSO vehicle control (open circles) or the indicated compound (solid circles, 5 mM
added at solid triangle). After 30 min, 5-HT (0.8 mM, grey triangle) was added. Following stabilization of the 5-HT response, forskolin (20 mM, open triangle) was added to each well.
(C) Dose-response curves show inhibition of 5-HT (0.8 mM) evoked cAMP generation in the presence of increasing concentration of individual aporphines.
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Table 1
IC50 values for aporphine derivatives screened against Sm.5HTRL and larval
schistosomules.
Compound IC50 Sm.5HTRL (mM) IC50 schistosomule (mM)
Nuciferine 0.24 ± 0.04 0.62 ± 0.22
D-glaucine 0.86 ± 0.22 3.9 ± 0.72
Boldine 1.1 ± 0.10 2.5 ± 1.4
Apomorphine 15.2 ± 3.3 24.2 ± 15.1
Bulbocapnine 15.2 ± 2.5 76.1 ± 17.8
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3.1. Several aporphinoids act as potent antagonists at Sm.5HTRL
Four commercially available aporphine natural products eFig. 2. Aporphine alkaloids inhibit schistosomule contractility. (A) Schistosomule body le
treated schistosomules (middle), and schistosomules exposed to both 5-HT and the Sm.5HT
basal conditions (white bars), addition of 5-HT (10 mM, black bars), and 5-HT plus increasinnuciferine, D-glaucine, boldine and bulbocapnine (Fig. 1A) e were
screened against recombinantly expressed Sm.5HTRL in
HEK293 cells. Apomorphine, a synthetic aporphine which we have
previously shown inhibits schistosomule contractility (Chan et al.,
2014), was also examined (Fig. 1A). To proﬁle the activity of
Sm.5HTRL, a cAMP-dependent luciferase reporter (pGloSensor-22F)
was co-expressed. Sm.5HTRL is Gs coupled in this system, permit-
ting a rapid and robust read out of 5-HT evoked cAMP generation in
live cells (Chan et al., 2016b).
None of the ﬁve compounds elevated cAMP levels when
administered to Sm.5HTRL at concentrations 100 mM (Fig. 1B).
However subsequent addition of 5-HT (0.8 mM) revealed blunted
responses to 5-HT in cells treated with the individual aporphine
ligands (Fig. 1B), suggesting an antagonist action at Sm.5HTRL. To
verify that aporphine-treated treated cells were viable and capablength traces were recorded over 1 min for untreated schistosomules (left), 5-HT (10 mM)
RL antagonist methiothepin (10 mM, right). (B) Quantiﬁcation of body contractions for
g doses of indicated aporphine (grey bars).
Fig. 3. Correlation of inhibition of Sm.5HTRL with inhibition of schistosomule
mobility. Measured IC50 for blockade of Sm.5HTRL by different aporphine derivatives
(ordinate) plotted against measurements of IC50 for inhibition of schistosomule
contractility (abscissa). Compounds: 1 ¼ nuciferine, 2 ¼ D-glaucine, 3 ¼ boldine,
4 ¼ apomorphine and 5 ¼ bulbocapnine. Data are ﬁtted to a linear equation
(y ¼ bxþa), slope ¼ 1.06 ± 0.11 (standard error).
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each case, forskolin elevated cAMP levels to a similar plateau. These
data suggest that incubation with aporphine ligands inhibited
Sm.5HTRL dependent cAMP production.
Complete dose inhibition relationships were then performed
to assess the potencies of Sm.5HTRL inhibition. Fig. 1C
demonstrates a dose-dependent inhibition of 5-HT-evoked
cAMP signaling with IC50 values across a ~10-fold range
(Table 1). The rank order of potency was nuciferine (IC50¼ 0.24 mM)
< D-glaucine (IC50 ¼ 0.86 mM) < boldine (IC50 ¼ 1.1 mM) <
bulbocapnine(IC50 ¼ 15.2 mM) ¼ apomorphine (IC50 ¼ 15.2 mM).3.2. Sm.5HTRL antagonists ablate schistosomule mobility
Next we screened the aporphine compounds against larval
schistosomules. Schistosomules comprise the parasite life cycle
stage after penetration of the deﬁnitive host by cercariae, and are
commonly used in drug screening assays since their periodic body
contractions provide a clear phenotypic readout. In this movement
assay, exogenous 5-HT stimulates contractility, and knockdown of
Sm.5HTRL (Patocka et al., 2014), or application of the known
Sm.5HTRL antagonist methiothepin (Fig. 2A (Chan et al., 2016b))
reversed this effect.
For quantifying the effects of the aporphine ligands, basal
schistosomule movement was ﬁrst recorded of worms in media
lacking 5-HT. 5-HT (10 mM) was then added, resulting in pro-
nounced contractility (~3e5 fold increase), after which increasing
doses of Sm.5HTRL antagonists were added (Fig. 2A). The dose
dependent effects of the individual aporphine compounds are
shown in Fig. 2B. Nuciferine and D-glaucine were particularly
effective at inhibiting larval contractions. Comparison of the po-
tency of these ligands at inhibiting Sm.5HTRL and larval mobility
was then assessed (Fig. 3, Table 1). This correlation demonstrated
that the most potent Sm.5HTRL blockers served as the mosteffective inhibitors of schistosomule contraction (Fig. 3, Table 1).
3.3. Effects of aporphine inhibitors of Sm.5HTRL on adult
schistosomes
Next, we screened the three most effective compounds (nuci-
ferine, D-glaucine and boldine, Fig. 3) against cultured adult
S. mansoni parasites. Adult S. mansoni also exhibit 5-HT dependent
motility which can be measured to quantify drug action (Patocka
et al., 2014; Chan et al., 2016b). Adult S. mansoni recovered from
infected mice were separated into single sex cohorts and the effects
of a ﬁxed concentration of drug (10 mM) on the basal motility of
males (Fig. 4A) or females (Fig. 4B) was examined. For males, all
drugs impaired basal movement to a similar extent (~50%)
compared with control worms (Fig. 4A). For females, nuciferine
appeared more effective than the other ligands (p < 0.01 versus
p < 0.05, Fig. 4B).
Finally, the effect of ligands on 5-HT stimulated motility was
examined. In control worms, 5-HT stimulated movement, most
evident in female worms (Fig. 4C&D). In male worms, each apor-
phinoid decreased responsiveness to increasing concentrations of
5-HT, with worms incubated in nuciferine showing no 5-HT stim-
ulated motility even at the highest 5-HT doses (1 mM). Sex-
speciﬁc difference were observed: with female worms, high doses
of 5-HT were competent at restoring motility after D-glaucine or
boldine treatment. In contrast, nuciferine again proved to be an
effective inhibitor of 5-HT stimulated motility in both female
(partial recovery 100 mM 5-HT) and male worms (nuciferine ac-
tion not reversed by 5-HT).
4. Discussion
4.1. Target-based discovery of natural products that are Sm.5HTRL
blockers
Natural product based drug discovery has provided critical
breakthroughs in the treatment of parasitic disease (Shen, 2015),
and there is considerable interest in mining the natural chemical
lexicon to identify antischistosomal compounds (Neves et al., 2015).
Here, we have studied the action of several aporphine alkaloid
natural products (nuciferine, D-glaucine, boldine and bulbo-
capnine) on 5-HT signaling in schistosomes, which identiﬁed
nuciferine as an effective inhibitor of GPCR signaling in vitro and 5-
HT evoked motility responses in intact parasites.
Nuciferine is one of many aporphine phytochemicals found in
the sacred lotus plant (Nelumbo nucifera). The leaves, ﬂowers, seeds
and rhizomes of these plants have been broadly used in traditional
medicine for treating a spectrum of ailments (Mukherjee et al.,
2009). Aporphine compounds isolated from Nelumbo nucifera
leaves have been previously shown to have anticestodal proﬁles,
with the mechanistic basis for these effects being ascribed to a free
radical scavenging effect (Lin et al., 2014). A more recent study
investigating the psychotropic properties of nuciferine demon-
strated an afﬁnity for several mammalian serotonergic GPCRs,
encompassing action as an inverse agonist at the human 5-HT7
receptor (Hs.5HT7R (Farrell et al., 2016)). Hs.5HT7R is the closest
human homolog of Sm.5HTRL, the abundantly expressed schisto-
some serotonergic GPCR that controls parasite movement (Patocka
et al., 2014; Chan et al., 2016b). Furthermore, our recent pharma-
cological proﬁling of Sm.5HTRL identiﬁed several compounds with
dimethoxyisoquinoline substructure that act as potent and effec-
tive Sm.5HTRL blockers (Chan et al., 2016b). It is therefore notable
that the most effective aporphinoid inhibitor of Sm.5HTRL was
nuciferine (contains dimethoxyisoquinoline substructure), fol-
lowed by two methoxyisolquinoline compounds (D-glaucine and
J.D. Chan et al. / International Journal for Parasitology: Drugs and Drug Resistance 6 (2016) 364e370 369boldine). The least effective aporphines were bulbocapnine and
apomorphine which lacked these moieties (Fig. 1, Table 1). Further
exploration of the tolerance of this pharmacophore for serotonergic
inhibition and antischistosomal activity is warranted. These results
also highlight the importance of optimization of the cAMP
biosensor assay for enabling target-based screening of Sm.5HTRL.
This methodology has identiﬁed leads with comparable potency
and penetrance to those generated from larger, more intensive,
phenotypic screens. While unbiased, phenotypic screens certainly
afford the opportunity for discovering new chemistry that conveys
antischistocidal activity, the trade off is often a poorer hit rate
(<0.01% (Mansour et al., 2016)).
4.2. Aporphinoid evoked hypomotility correlates with Sm.5HTRL
inhibition
The ability to use the cAMP biosensor to identify Sm.5HTRL li-
gands through heterologous expression screening has provided
new tools for probing the roles of Sm.5HTRL in vivo. Sm.5HTR is
expressed in (i) the nerves innervating the male body wall, (ii) the
male sucker, which is required for anchoring the male-female pairFig. 4. Aporphine alkaloid inhibition of adult schistosome movement. Effects of prioriti
male and (B) female worms treated with either DMSO (‘ctrl’) or the indicated compound
stimulation of (C) male and (D) female adult schistosome movement (expressed as fold chto host vasculature, and (iii) the female caecum, which is involved
in the continuous ingestion of red-blood cells from the host cir-
culation (Patocka et al., 2014). These roles for Sm.5HTR are broadly
similar to the role reported for the Caenorhabditis elegans SER-7
homolog, which regulates neuromuscular signaling to the body
wall and feeding behavior (Hobson et al., 2006).
Nuciferine, D-glaucine and boldine completely blocked
Sm.5HTRL dependent cAMP generation in vitro (Fig. 1), and
completely ablated schistosome motility (Fig. 2). These data are
consistent with the observations of Patocka et al. who used in vivo
RNAi methods to demonstrate the key role of Sm.5HTR in sup-
porting larval motility (Patocka et al., 2014). The strong correlation
between potency of ligands effecting Sm.5HTRL blockade and
schistosomule inhibition (Fig. 3) underscores the importance of this
speciﬁc GPCR in regulating motility at this life cycle stage (Patocka
et al., 2014). In adults, the ability of Sm.5HTRL ligands to inhibit
basal motility is less (~50%, Fig. 4), possibly indicating the
involvement of additional mechanisms governing adult worm
muscle activity. Again this result is consistent with in vivo RNAi data
(Patocka et al., 2014). Differences in Sm.5HTRL expression, rates of
5-HT uptake and different drug absorption kinetics between malezed compounds on male and female adult schistosome worms. Basal movement of (A)
(10 mM, 2 h). *p < 0.05, **p < 0.01. Effect of aporphine antagonists on 5-HT evoked
ange over basal movement for DMSO control cohort).
J.D. Chan et al. / International Journal for Parasitology: Drugs and Drug Resistance 6 (2016) 364e370370and female adult worms may also contribute to observed differ-
ences in effectiveness of individual compounds (Fig. 4). Overall, it is
the consistent inhibitory effect of nuciferine against larvae, as well
as basal and 5-HT stimulated adult worm motility that is note-
worthy. These observations support additional investigation of
nuciferine, and related methoxyisoquinoline aporphinoids, as po-
tential anthelmintic agents.
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